Celgene

company

About

Celgene discovers, develops and commercializes innovative therapies to treat cancer and immune-inflammatory-related diseases.

  • 10001 - max

Highlights

Details

Industries
Biotechnology,Medical
Founded date
Jan 1, 1986
Number Of Employee
10001 - max
Operating Status
Active

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options.

There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma.

In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

Investments

Number of Investments
Number of Lead Investments
9
0
Celgene has made 9 investments. Their most recent investment was on Dec 21, 2017, when Rapt Therapeutics raised $60M.
Date Company Name
Round Money Raised Industry Lead Investor
Dec 21, 2017 Rapt Therapeutics
Series C $60M Biotechnology
Nov 13, 2017 Arcus Biosciences
Series C $107M Biotechnology
Jul 11, 2017 Evelo Biosciences
Series B $50M Biotechnology
Series B $70M Biotechnology
May 24, 2016 COTA Healthcare
Series B Artificial Intelligence